Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction

JAMA

Volumn 297, Issue 2, 2007, Pages 177-186

  Rasmussen, Jeppe N ^a,e   Chong, Alice ^a   Alter, David A ^a,b,c,d  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; AGED; ARTICLE; CANADA; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SOCIAL ASPECT; SURVIVOR;

EID: 33846123697     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.2.177     Document Type: Article

References (40)

1. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737.
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
4. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
5. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation2006;113:203-212.
6. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88:229-233.
7. Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf. 2004;13:761-766.
8. Garcia de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30:105-110.
9. Dobbels F, De Geest S, van Cleemput J, Droogne W, Vanhaecke J. Effect of late medication non-compliance on outcome after heart transplantation: a 5-year follow-up. J Heart Lung Transplant. 2004;23:1245-1251.
10. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842-1847.
11. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841.
12. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864-1870.
13. Bertolet BD. Calcium antagonists in the post-myocardial infarction setting. Drugs Aging. 1999;15:461-470.
14. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.
15. Alter DA, Iron K, Austin PC, Naylor CD. Socioeconomic status, service patterns, and perceptions of care among survivors of acute myocardial infarction in Canada. JAMA. 2004;291:1100-1107.
16. Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care. 2002;8(10)(suppl):S249-S254.
17. Tu JV, Austin PC, Naylor CD, Iron K, Zhang H. Acute myocardial infarction outcomes in Ontario. In: Naylor CD, Slaughter PM, eds. Cardiovascular Health and Services in Ontario: An ICES Atlas. Toronto, Ontario: Institute for Clinical Evaluative Sciences; 1999:83-110.
18. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with st-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
19. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36:970-1062.
20. Tu JV, Austin PC, Walld R, et al. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol. 2001;37:992-997.
21. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-1078.
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
23. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
24. MacKillop WJ, Zhang-Salomons J, Boyd CJ, Groome PA. Associations between community income and cancer incidence in Canada and the United States. Cancer. 2000;89:901-912.
25. Mickley H, Eiskjaer H, Botker HE. Is an additional post-myocardial infarction β-blocker trial required in the era of early revascularization? Eur Heart J. 2004;25:96-97.
26. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
27. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707-1714.
28. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-1131.
29. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153-1158.
30. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145:438-444.
31. Peterson AM, McGhan WF. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics. 2005;23:13-25.
32. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8)(suppl 1):52C-60C.
33. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.
34. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794-811.
35. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes: a critical review. Arch Intern Med. 1997;157:1921-1929.
36. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
37. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997;50:619-625.
38. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
39. West SL, Savitz DA, Koch G, et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995;142:1103-1112.
40. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-2571.